- Home
- APVO vs XBIO Comparison
APVO vs XBIO Comparison
Compare APVO & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- XBIO
- Stock Information
- Founded
- APVO 2016
- XBIO N/A
- Country
- APVO United States
- XBIO United States
- Employees
- APVO N/A
- XBIO N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- XBIO Health Care
- Exchange
- APVO Nasdaq
- XBIO Nasdaq
- Market Cap
- APVO 5.4M
- XBIO 5.8M
- IPO Year
- APVO N/A
- XBIO N/A
- Fundamental
- Price
- APVO $1.38
- XBIO $2.67
- Analyst Decision
- APVO Strong Buy
- XBIO Hold
- Analyst Count
- APVO 1
- XBIO 1
- Target Price
- APVO $296.00
- XBIO N/A
- AVG Volume (30 Days)
- APVO 1.2M
- XBIO 6.9K
- Earning Date
- APVO 05-07-2025
- XBIO 03-18-2025
- Dividend Yield
- APVO N/A
- XBIO N/A
- EPS Growth
- APVO N/A
- XBIO N/A
- EPS
- APVO N/A
- XBIO N/A
- Revenue
- APVO N/A
- XBIO $2,500,284.00
- Revenue This Year
- APVO N/A
- XBIO N/A
- Revenue Next Year
- APVO N/A
- XBIO $27.78
- P/E Ratio
- APVO N/A
- XBIO N/A
- Revenue Growth
- APVO N/A
- XBIO N/A
- 52 Week Low
- APVO $0.94
- XBIO $2.26
- 52 Week High
- APVO $180.19
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- APVO 31.11
- XBIO 27.60
- Support Level
- APVO $0.94
- XBIO $3.25
- Resistance Level
- APVO $2.64
- XBIO $3.43
- Average True Range (ATR)
- APVO 0.45
- XBIO 0.24
- MACD
- APVO -0.07
- XBIO -0.08
- Stochastic Oscillator
- APVO 16.42
- XBIO 25.63
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.